Is TransMedics Group (TMDX) Fairly Valued As Revenue Grew And 2026 Guidance Was Raised?
TransMedics Group (TMDX) is back in focus after reporting second quarter 2026 results that combined higher revenue with lower net income, along with a raised lower end for full year revenue guidance.
See our latest analysis for TransMedics Group.
The mixed second quarter numbers and higher revenue guidance have arrived after a volatile spell for TransMedics Group, with a 19.74% 30 day share price return and a 29.62% 90 day share price return contrasting with a year to date share price return that is down 27.80%. Over a longer horizon, the total shareholder return is down 30.55% over one year, but up 35.40% over three years and 229.05% over five years, which signals that long term holders have still seen meaningful gains despite recent pressure.
If this earnings update has you reassessing growth potential in medical technology, it can be useful to see how other healthcare focused AI opportunities compare using our 42 healthcare AI stocks
After TransMedics Group shares climbed on higher revenue and a raised guidance floor, yet still trade below both intrinsic and analyst estimates, is the discount pointing to opportunity, or is the market correctly pricing in caution about earnings quality and volatility?
Most Popular Narrative: 9% Undervalued
The most followed narrative currently pegs TransMedics Group's fair value at $97.30 compared with a last close of $88.58, which puts a modest discount under the spotlight for anyone weighing the new guidance against longer term assumptions.
Expansion into new organ types (notably kidney) and next-generation product launches (Gen 3 OCS platforms for heart, lung, and liver) are expected to materially grow TransMedics' total addressable market, improve product mix, and support higher average selling prices, benefiting earnings and longer-term net margins.
Curious what sits behind that growth story? The narrative leans on transplant volume trends, margin normalisation, and a future profit multiple that differs from today. Want to see which assumptions really carry the $97.30 fair value?
That narrative uses a discount rate of about 8% to pull expected future earnings back into today's dollars, then compares the implied value with the current share price. It also relies on projected revenue growth, a lower profit margin than today, and a future P/E multiple that is below the current US Medical Equipment sector level but above TransMedics Group's present ratio.
With the fair value sitting around 9% above the last close, the narrative points to some potential upside, but it also embeds specific expectations about transplant volumes, international rollout and how much investors might pay for earnings several years from now.
Result: Fair Value of $97.30 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this picture for TransMedics Group could change quickly if regulatory scrutiny on organ procurement tightens or if new competitors pressure pricing and margins.
Find out about the key risks to this TransMedics Group narrative.
Next Steps
If this combination of caution and optimism around TransMedics Group has you thinking differently, act promptly and review the full breakdown of the company's 4 key rewards
Looking for more investment ideas beyond TransMedics Group?
Do not stop with TransMedics Group. Use the Simply Wall St screener to uncover fresh opportunities that could suit your goals before the market moves on.
- Spot potential value opportunities early and check out the 52 high quality undervalued stocks that combine solid fundamentals with discounted prices.
- Prioritise resilience and review the 80 resilient stocks with low risk scores to see companies with lower risk scores that might help steady your portfolio.
- Hunt for underfollowed opportunities and scan the screener containing 20 high quality undiscovered gems before others catch on to their quality.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com